geographic atrophy

Annexon reports topline results from Phase II trial of geographic atrophy therapy
Annexon reports topline results from Phase II trial of geographic atrophy therapy
Clinical Trials Arena
Annexon
clinical trials
ANX007
vision loss
geographic atrophy
Flag link:
Apellis reports strong start for new vision loss drug
Apellis reports strong start for new vision loss drug
BioPharma Dive
Apellis Pharmaceuticals
Syfovre
geographic atrophy
Flag link:
Playing catch-up, Boehringer taps RetinAI for AI boost to eye disease R&D
Playing catch-up, Boehringer taps RetinAI for AI boost to eye disease R&D
Fierce Biotech
Boehringer Ingelheim
RetinAI
artificial intelligence
geographic atrophy
R&D
Flag link:
FDA accepts Iveric Bio's NDA, grants priority review for GA drug
FDA accepts Iveric Bio's NDA, grants priority review for GA drug
Endpoints
Iveric Bio
FDA
geographic atrophy
Apellis Pharmaceuticals
avacincaptad pegol
Flag link:
FDA Approves Apellis' Syfovre as First Treatment for Geographic Atrophy
FDA Approves Apellis' Syfovre as First Treatment for Geographic Atrophy
BioSpace
Apellis Pharmaceuticals
Syfovre
pegcetacoplan
FDA
geographic atrophy
Flag link:
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail
Fierce Biotech
Merck
NGM Biopharmaceuticals
clinical trials
eye disease
NGM621
geographic atrophy
Flag link:
Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy
Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy
Fierce Pharma
Genentech
geographic atrophy
clinical trials
OpRegen
cell therapy
Flag link:
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
Investors Business Daily
Apellis Pharmaceuticals
pegcetacoplan
eye disease
geographic atrophy
Flag link:
Roche Scraps Mid-Phase Programs in Hepatitis B, Geographic Atrophy
Roche Scraps Mid-Phase Programs in Hepatitis B, Geographic Atrophy
BioSpace
Roche
hepatitis B
geographic atrophy
Flag link:
Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market
Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market
Fierce Biotech
Iveric Bio
Apellis Pharmaceuticals
clinical trials
FDA
dry eye disease
geographic atrophy
Flag link:
Apellis Surges By Double Digits As FDA Mulls Its Eye-Disease Treatment
Apellis Surges By Double Digits As FDA Mulls Its Eye-Disease Treatment
Investors Business Daily
Apellis Pharmaceuticals
geographic atrophy
FDA
pegcetacoplan
Flag link:
Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month data
Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month data
Fierce Pharma
Apellis
pegcetacoplan
geographic atrophy
FDA
Flag link:
Apellis eye drug succeeds in one key study, but falls short in its twin
Apellis eye drug succeeds in one key study, but falls short in its twin
BioPharma Dive
Apellis Pharmaceuticals
FDA
pegcetacoplan
geographic atrophy
Flag link:
Janssen buys up eye disorder gene therapy asset from Hemera Biosciences
Janssen buys up eye disorder gene therapy asset from Hemera Biosciences
Fierce Biotech
Janssen
JNJ
Hemera Biosciences
gene therapy
HMR59
geographic atrophy
Flag link:
Why Iveric Bio Is Skyrocketing 24% Today
Why Iveric Bio Is Skyrocketing 24% Today
Motley Fool
Iveric Bio
geographic atrophy
Zimura
Flag link:
Boehringer Ingelheim collaborates with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy
Boehringer Ingelheim collaborates with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy
Pharmaceutical Business Review
Boehringer Ingelheim
CDR-Life
antibody fragments
geographic atrophy
R&D
Flag link: